Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022
Cross-posted from Centers for Disease Control and Prevention
On Friday, September 9, 2022, CDC issued in its Morbidity and Mortality Weekly Report (MMWR) the results of a study of the clinical use of tecovirimat (Tpoxx). A summary of the study appears below from the MMWR.
What is already known about this topic?
Tecovirimat (Tpoxx) was approved by the Food and Drug Administration for treatment of smallpox based on data obtained from animal models; there are no safety or efficacy data regarding its use in patients with Monkeypox virus infection.
What is added by this report?
Among 549 patients with Monkeypox virus infection treated with tecovirimat under an Expanded Access Investigational New Drug protocol, 99.8% received it orally as an outpatient. Among 369 patients, few adverse events were reported.
What are the implications for public health practice?
Tecovirimat is generally well tolerated, and these data support continued access to treatment with tecovirimat during the current monkeypox outbreak.
Read the complete report here. Please visit CDC.gov for treatment guidelines and updated information on Monkeypox in the U.S.